RNase-L control of cellular mRNAs: Roles in biologic functions and mechanisms of substrate targeting

Journal of Interferon and Cytokine Research

Volumn 34, Issue 4, 2014, Pages 275-288

  Brennan Laun, Sarah E ^a,b   Ezelle, Heather J ^a,b   Li, Xiao Ling ^c   Hassel, Bret A ^a,b  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HU ANTIGEN; MESSENGER RNA; MYOGENIN; PROTEIN KINASE R; RIBONUCLEASE L; RNA BINDING PROTEIN; TRISTETRAPROLIN; 2-5A-DEPENDENT RIBONUCLEASE; INTERFERON; RIBONUCLEASE; VIRUS RNA;

BIOCHEMISTRY; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SUBSTRATE; GENE; GENE EXPRESSION; HUMAN; INTERFERON STIMULATED GENE15; INTERFERON STIMULATED GENE43; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIBOSOME; RNA STABILITY; RNA TRANSLATION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CELL PROLIFERATION; ENZYME SPECIFICITY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; VIRUS INFECTION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDORIBONUCLEASES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; MALE; RNA, MESSENGER; RNA, VIRAL; SUBSTRATE SPECIFICITY; VIRUS DISEASES;

EID: 84898721361     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0147     Document Type: Review

References (127)

1. Al-AhmadiW, Al-Haj L, Al-Mohanna FA, Silverman RH, Khabar KSA. 2009. RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth. Oncogene 28(15):1782-1791.
2. Al-Haj L, Blackshear PJ, Khabar KSA. 2012. Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements. Nucleic Acids Res 40(16):7739-7752.
3. Ali MMU, Bagratuni T, Davenport EL, Nowak PR, Silva-Santisteban MC, Hardcastle A, McAndrews C, Rowlands MG, Morgan GJ, Aherne W, Collins I, Davies FE, Pearl LH. 2011. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. Embo J 30(5): 894-905.
4. Andersen JB,Mazan-Mamczarz K, Zhan M, GorospeM,HasselBA. 2009. Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. RNA Biol 6(3):305-315.
5. Anderson P, Kedersha N. 2002. Visibly stressed: the role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress & Chaperones 7(2):213-221.
6. Baglioni C, Minks MA, Maroney PA. 1978. Interferon action may be mediated by activation of a nuclease by pppA2¢-p5¢A2¢p5¢A. Nature 273(22):3.
7. Bisbal C, Martinand C, Silhol M, Lebleu B, Salehzada T. 1995. Cloning and characterization of a Rnase-L inhibitor-a new Component of the interferon-regulated 2-5a pathway. J Biol Chem 270(22):13308-13317.
8. Bisbal C, Silhol M, Laubenthal K, Kaluza T, Carnac G, Milligan L, Le Roy F, Salehzada T. 2000. The 2¢-5¢ oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol 20(14):4959-4969.
9. Bisbal C, Silverman RH. 2007. Diverse functions of RNase L and implications in pathology. Biochimie 89(6-7):789-798.
10. Brennan CM, Steitz JA. 2001. HuR and mRNA stability. Cell Mol Life Sci 58(2):266-277.
11. Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. 2009. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res 69(12):5168-5176.
12. Brooks SA, Blackshear PJ. 2013. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim Biophys Acta-Gene Regul Mech 1829(6-7):666-679.
13. Brooks SA, Connolly JE, Rigby WF. 2004. The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. J Immunol 172(12):7263-7271.
14. Carballo E, Lai WS, Blackshear PJ. 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95(6):1891-1899.
15. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J. 2002. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30(2):181-184.
16. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS. 2002. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32(4):582-583.
17. Castelli JC, Hassel BA, Wood KA, Li XL, Amemiya K, Dalakas MC, Torrence PF, Youle RJ. 1997. A study of the interferon antiviral mechanism: Apoptosis activation by the 2-5A system. J Exp Med 186(6):967-972.
18. Chakrabarti A, Jha BK, Silverman RH. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 31(1):49-57.
19. Chase BI, Zhou Y, Xiang Y, Silverman RH, Zhou A. 2003. Proteasome-mediated degradation of RNase L in response to phorbol-12-myristate- 13-acetate (PMA) treatment of mouse L929 cells. J Interferon Cytokine Res 23(10):565-573.
20. Chaudhary SKMaJ. 2012. Abstract C57: The expression of 2¢5¢-oligoadenylate synthetase in prostate cancer and its effect on prostate cancer cell cycle. Cancer Res 72.
21. Chen CY, Shyu AB. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20(11):465-470.
22. Chu PC, Chuang HC, Kulp SK, Chen CS. 2012. The mRNAstabilizing factor HuR protein is targeted by beta-TrCP protein for degradation in response to glycolysis inhibition. J Biol Chem 287(52):43639-43650.
23. Clemens MJ, Williams BR. 1978. Inhibition of cell-free protein synthesis by pppA2¢p5¢A2¢p5¢A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell 13(3): 565-572.
24. Cockman ME, Webb JD, Ratcliffe PJ. 2009. FIH-dependent asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Hypoxia and Consequences from Molecule to Malady 1177:9-18.
25. Domingo-Gil E, Gonzalez JM, Esteban M. 2010. Identification of cellular genes induced in human cells after activation of the OAS/RNaseL pathway by vaccinia virus recombinants expressing these antiviral enzymes. J Interferon Cytokine Res 30(3):171-188.
26. Dong B, Niwa M, Walter P, Silverman RH. 2001. Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p. RNA 7(3):361-373.
27. Dong B, Silverman RH. 1995. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 270(8):4133-4137.
28. Dong B, Silverman RH. 1997. A bipartite model of 2-5Adependent RNase L. J Biol Chem 272(35):22236-22242.
29. Dong B, Silverman RH. 1999. Alternative function of a protein kinase homology domain in 2¢,5¢-oligoadenylate-dependent RNase L. Nucleic Acids Res 27(2):439-445.
30. Dong J, Lai R, Nielsen K, Fekete CA, Qiu H, Hinnebusch AG. 2004. The essential ATP-binding cassette protein RLI1 functions in translation by promoting preinitiation complex assembly. J Biol Chem 279(40):42157-42168.
31. DuBois RN, McLane MW, Ryder K, Lau LF, Nathans D. 1990. A growth factor-inducible nuclear protein with a novel cysteine/histidine repetitive sequence. J Biol Chem 265(31): 19185-19191.
32. Ezelle HJ, Hassel BA. 2012. Pathologic effects of RNase-L dysregulation in immunity and proliferative control. Front Biosci (Schol Ed) 4:767-786.
33. Fabre O, Salehzada T, Lambert K, Boo Seok Y, Zhou A, Mercier J, Bisbal C. 2012. RNase L controls terminal adipocyte differentiation, lipids storage and insulin sensitivity via CHOP10 mRNA regulation. Cell Death Differ 19(9): 1470-1481.
34. Feng XB, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen WL, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. 2006. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54(9):2951-2962.
35. Fialcowitz EJ, Brewer BY, Keenan BP, Wilson GM. 2005. A hairpin-like structure within an AU-rich mRNA-destabilizing element regulates trans-factor binding selectivity and mRNA decay kinetics. J Biol Chem 280(23):22406-22417.
36. Figueroa A, Cuadrado A, Fan J, Atasoy U, Muscat GE, Munoz-Canoves P, Gorospe M, Munoz A. 2003. Role of HuR in skeletal myogenesis through coordinate regulation of muscle differentiation genes. Mol Cell Biol 23(14):4991-5004.
37. Floyd-Smith G, Slattery E, Lengyel P. 1981. Interferon action: RNA cleavage pattern of a (2¢-5¢)oligoadenylate-dependent endonuclease. Science 212(4498):1030-1032.
38. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. 2003. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 100(2):171-194.
39. Galban S, Kuwano Y, Pullmann R, Martindale JL, Kim HH, Lal A, Abdelmohsen K, Yang XL, Dang YJ, Liu JO, Lewis SM, Holcik M, Gorospe M. 2008. RNA-Binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1 alpha. Mol Cell Biol 28(1):93-107.
40. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. 2006. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70(4):1032-1060.
41. Gonzalez-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat Rev Immunol 12(2):125-135.
42. Gribaudo G, Lembo D, Cavallo G, Landolfo S, Lengyel P. 1991. Interferon action-binding of viral-Rna to the 40-kilodalton 2¢-5¢-oligoadenylate synthetase in interferon-treated hela-cells infected with encephalomyocarditis virus. J Virol 65(4):1748-1757.
43. Guhaniyogi J, Brewer G. 2001. Regulation of mRNA stability in mammalian cells. Gene 265(1-2):11-23.
44. Han YC, Whitney G, Donovan J, Korennykh A. 2012. Innate immune messenger 2-5A tethers human RNase L into active high-order complexes. Cell Rep 2(4):902-913.
45. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. 1993. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12(8):3297-3304.
46. Henras AK, Soudet J, Gerus M, Lebaron S, Caizergues-Ferrer M, Mougin A, Henry Y. 2008. The post-transcriptional steps of eukaryotic ribosome biogenesis. Cell Mol Life Sci 65(15): 2334-2359.
47. Hovanessian AG. 2007. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2¢-5¢oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev 18(5-6):351-361.
48. Hovanessian AG, Laurent AG, Chebath J, Galabru J, Robert N, Svab J. 1987. Identification of 69-Kd and 100-Kd Forms of 2-5a Synthetase in Interferon-Treated Human-Cells by Specific Monoclonal-Antibodies. EMBO J 6(5):1273-1280.
49. Jha BK, Polyakova I, Kessler P, Dong B, Dickerman B, Sen GC, Silverman RH. 2011. Inhibition of RNase L and RNAdependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J Biol Chem 286(30):26319-26326.
50. Khabar KS, Siddiqui YM, al-Zoghaibi F, al-Haj L, Dhalla M, Zhou A, Dong B, Whitmore M, Paranjape J, Al-Ahdal MN, Al-Mohanna F, Williams BR, Silverman RH. 2003. RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR. J Biol Chem 278(22):20124-20132.
51. Kim CW, Vo MT, Kim HK, Lee HH, Yoon NA, Lee BJ, Min YJ, Joo WD, Cha HJ, Park JW, Cho WJ. 2012. Ectopic overexpression of tristetraprolin in human cancer cells promotes biogenesis of let-7 by down-regulation of Lin28. Nucleic Acids Res 40(9):3856-3869.
52. Kishore S, Jaskiewicz L, Burger L, Hausser J, Khorshid M, Zavolan M. 2011. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat Methods 8(7):559-564.
53. Kispal G, Sipos K, Lange H, Fekete Z, Bedekovics T, Janaky T, Bassler J, Netz DJA, Balk J, Rotte C, Lill R. 2005. Biogenesis of cytosolic ribosomes requires the essential iron-sulphur protein Rli1p and mitochondria. EMBO J 24(3):589-598.
54. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R. 2011. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J Interferon Cytokine Res 31(1):41-47.
55. Kubota K, Nakahara K, Ohtsuka T, Yoshida S, Kawaguchi J, Fujita Y, Ozeki Y, Hara A, Yoshimura C, Furukawa H, Haruyama H, Ichikawa K, Yamashita M, Matsuoka T, Iijima Y. 2004. Identification of 2¢-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon. J Biol Chem 279(36):37832-37841.
56. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19(6):4311-4323.
57. Lai WS, Stumpo DJ, Blackshear PJ. 1990. Rapid insulin-stimulated accumulation of an mRNA encoding a proline-rich protein. J Biol Chem 265(27):16556-16563.
58. Le Roy F, Bisbal C, Silhol M, Martinand C, Lebleu B, Salehzada T. 2001. The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells. J Biol Chem 276(51):48473-48482.
59. Le Roy F, Salehzada T, Bisbal C, Dougherty JP, Peltz SW. 2005. A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol 12(6):505-512.
60. Lee H, Komano J, Saitoh Y, Yamaoka S, Kozaki T, Misawa T, Takahama M, Satoh T, Takeuchi O, Yamamoto N, Matsuura Y, Saitoh T, Akira S. 2013a. Zinc-finger antiviral protein mediates retinoic acid inducible gene I-like receptor-independent antiviral response to murine leukemia virus. Proc Natl Acad Sci USA 110(30):12379-12384.
61. Lee TY, Ezelle HJ, Venkataraman T, Lapidus RG, Scheibner KA, Hassel BA. 2013b. Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia. J Interferon Cytokine Res 33(1): 34-42.
62. Li XL, Andersen JB, Ezelle HJ, Wilson GM, Hassel BA. 2007. Post-transcriptional regulation of RNase-L expression is mediated by the 3¢-untranslated region of its mRNA. J Biol Chem 282(11):7950-7960.
63. Li XL, Blackford JA, Hassel BA. 1998. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol 72(4):2752-2759.
64. Li XL, Blackford JA, Judge CS, Liu M, Xiao W, Kalvakolanu DV, Hassel BA. 2000. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J Biol Chem 275(12): 8880-8888.
65. Li XL, Ezelle HJ, Kang TJ, Zhang L, Shirey KA, Harro J, Hasday JD, Mohapatra SK, Crasta OR, Vogel SN, Cross AS, Hassel BA. 2008. An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity. Proc Natl Acad Sci USA 105(52):20816-20821.
66. Liu LQ, Ilaria R Jr., Kingsley PD, Iwama A, van Etten RA, Palis J, Zhang DE. 1999. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETOexpressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 19(4):3029-3038.
67. Long TM, Chakrabarti A, Ezelle HJ, Brennan-Laun SE, Raufman JP, Polyakova I, Silverman RH, Hassel BA. 2013. RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer. Inflamm Bowel Dis 19(6):1295-1305.
68. Mahat DB, Brennan-Laun SE, Fialcowitz-White EJ, Kishor A, Ross CR, Pozharskaya T, Rawn JD, Blackshear PJ, Hassel BA, Wilson GM. 2012. Coordinated expression of tristetraprolin post-transcriptionally attenuates mitogenic induction of the oncogenic Ser/Thr kinase Pim-1. Plos One 7(3).
69. Maitra RK, Mcmillan NAJ, Desai S, Mcswiggen J, Hovanessian AG, Sen G, Williams BRG, Silverman RH. 1994. Hiv-1 Tar RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology 204(2):823-827.
70. Malathi K, Dong B, Gale M, Jr., Silverman RH. 2007. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448(7155):816-819.
71. Malathi K, Paranjape JM, Bulanova E, Shim M, Guenther-Johnson JM, Faber PW, Eling TE, Williams BR, Silverman RH. 2005. A transcriptional signaling pathway in the IFN system mediated by 2¢-5¢-oligoadenylate activation of RNase L. Proc Natl Acad Sci USA 102(41):14533-14538.
72. Malathi K, Saito T, Crochet N, Barton DJ, Gale M, Silverman RH. 2010. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA-a Publication of the RNA Society 16(11):2108-2119.
73. Mandal S, Abebe F, Chaudhary J. 2011. 2¢-5¢ oligoadenylate synthetase 1 polymorphism is associated with prostate cancer. Cancer 117(24):5509-5518.
74. Mazan-Mamczarz K, Galban S, de Silanes IL, Martindale JL, Atasoy U, Keene JD, Gorospe M. 2003. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA 100(14): 8354-8359.
75. Molinaro RJ, Jha BK, Malathi K, Varambally S, Chinnaiyan AM, Silverman RH. 2006. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2¢,5¢-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Res 34(22):6684-6695.
76. Nakajima K, Wall R. 1991. Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma. Mol Cell Biol 11(3):1409-1418.
77. Nakanishi M, Yoshimura A, Ishida N, Ueno Y, Kitade Y. 2004. Contribution of Tyr712 and Phe716 to the activity of human RNase l. European Journal of Biochemistry 271(13):2737-2744.
78. Nilsen TW, Baglioni C. 1979. Mechanism for discrimination between viral and host mRNA in interferon-treated cells. Proc Natl Acad Sci USA 76(6):2600-2604.
79. Nilsen TW, Maroney PA, Baglioni C. 1981. Double-stranded RNA causes synthesis of 2¢,5¢-oligo(A) and degradation of messenger RNA in interferon-treated cells. J Biol Chem 256(15):7806-7811.
80. Nilsen TW, Maroney PA, Baglioni C. 1982. Synthesis of (2¢-5¢)oligoadenylate and activation of an endoribonuclease in interferon-treated HeLa cells infected with reovirus. J Virol 42(3):1039-1045.
81. Nurenberg E, Tampe R. 2013. Tying up loose ends: ribosome recycling in eukaryotes and archaea. Trends Biochem Sci 38(2):64-74.
82. Ogawa K, Chen F, Kim YJ, Chen Y. 2003. Transcriptional regulation of tristetraprolin by transforming growth factorbeta in human T cells. J Biol Chem 278(32):30373-30381.
83. Pandey M, Rath PC. 2004. Expression of interferon-inducible recombinant human RNase L causes RNA degradation and inhibition of cell growth in Escherichia coli. Biochem Biophys Res Commun 317(2):586-597.
84. Paschoud S, Dogar AM, Kuntz C, Grisoni-Neupert B, Richman L, Kuhn LC. 2006. Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1. Mol Cell Biol 26(22):8228-8241.
85. Paukku K, Backlund M, De Boer RA, Kalkkinen N, Kontula KK, Lehtonen JYA. 2012. Regulation of AT1R expression through HuR by insulin. Nucleic Acids Res 40(12):5250-5261.
86. Pisarev AV, Skabkin MA, Pisareva VP, Skabkina OV, Rakotondrafara AM, Hentze MW, Hellen CU, Pestova TV. 2010. The role of ABCE1 in eukaryotic posttermination ribosomal recycling. Mol Cell 37(2):196-210.
87. Pisareva VP, Skabkin MA, Hellen CU, Pestova TV, Pisarev AV. 2011. Dissociation by Pelota, Hbs1 and ABCE1 of mammalian vacant 80S ribosomes and stalled elongation complexes. EMBO J 30(9):1804-17.
88. Putland RA, Sassinis TA, Harvey JS, Diamond P, Coles LS, Brown CY, Goodall GJ. 2002. RNA destabilization by the granulocyte colony-stimulating factor stem-loop destabilizing element involves a single stem-loop that promotes deadenylation. Mol Cell Biol 22(6):1664-1673.
89. Qi MY, Wang ZZ, Zhang Z, Shao Q, Zeng A, Li XQ, Li WQ, Wang C, Tian FJ, Li Q, Zou J, Qin YW, Brewer G, Huang S, Jing Q. 2012. AU-rich-element-dependent translation repression requires the cooperation of tristetraprolin and RCK/P54. Mol Cell Biol 32(5):913-28.
90. Ross CR, Brennan-Laun SE, Wilson GM. 2012. Tristetraprolin: Roles in cancer and senescence. Ageing Res Rev 11(4):473-484.
91. Ross J. 1995. mRNA stability in mammalian cells. Microbiol Rev 59(3):423-50.
92. Rusch L, Dong B, Silverman RH. 2001. Monitoring activation of ribonuclease L by 2¢,5¢-oligoadenylates using purified recombinant enzyme and intact malignant glioma cells. Methods Enzymol 342:10-20.
93. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat Rev Immunol 8(7):559-568.
94. Salehzada T, Cambier L, Vu Thi N, Manchon L, Regnier L, Bisbal C. 2009. Endoribonuclease L (RNase L) regulates the myogenic and adipogenic potential of myogenic cells. PLoS One 4(10):e7563.
95. Salehzada T, Silhol M, Lebleu B, Bisbal C. 1991. Polyclonal antibodies against Rnase-L-subcellular-localization of this enzyme in mouse cells. J Biol Chem 266(9):5808-5813.
96. Sawaoka H, Dixon DA, Oates JA, Boutaud O. 2003. Tristetraprolin binds to the 3¢-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J Biol Chem 278(16):13928-13935.
97. Shetzline SE, Suhadolnik RJ. 2001. Characterization of a 2¢,5¢-oligoadenylate (2-5A)-dependent 37-kDa RNase L. Azido photoaffinity labeling and 2-5A-dependent activation. (vol 276, pg 23707, 2001). J Biol Chem 276(34):32392-32392.
98. Silverman RH, Skehel JJ, James TC, Wreschner DH, Kerr IM. 1983. rRNA cleavage as an index of ppp(A2¢p)nA activity in interferon-treated encephalomyocarditis virus-infected cells. J Virol 46(3):1051-1055.
99. Simmons, G, Glynn SA, Komaroff AL, Mikovits JA, Tobler LH, Hackett J, Tang N, Switzer WM, Heneine W, Hewlett IK, Zhao J, Lo SC, Alter HJ, Linnen JM, Gao K, Coffin JM, Kearney MF, Ruscetti FW, Pfost MA, Bethel J, Kleinman S, Holmberg JA, Busch MP, Blood XMRV Scientific Research Working Group (SRWG). 2011 Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science. 2011 334(6057):814-817.
100. Sonenberg N, Dever TE. 2003. Eukaryotic translation initiation factors and regulators. Curr Opin Struct Biol 13(1):56-63.
101. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
102. Sukumar NA. 1991. Regulation of 2-5A dependent RNase at the level of its phosphorylation In Department of Pathology Uniformed Services University of the Health Sciences122.
103. Suswam E, Li Y, Zhang X, Gillespie GY, Li X, Shacka JJ, Lu L, Zheng L, King PH. 2008. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res 68(3):674-682.
104. Suzuki K, Nakajima H, Ikeda K, Maezawa Y, Suto A, Takatori H, Saito Y, Iwamoto I. 2003. IL-4-Stat6 signaling induces tristetraprolin expression and inhibits TNF-alpha production in mast cells. J Exp Med 198(11):1717-27.
105. Tanaka N, Nakanishi M, Kusakabe Y, Goto Y, Kitade Y, Nakamura KT. 2004. Structural basis for recognition of 2¢,5¢-linked oligoadenylates by human ribonuclease L. EMBO J 23(20):3929-3938.
106. Tang QQ, Lane MD. 2000. Role of C/EBP homologous protein (CHOP-10) in the programmed activation of CCAAT/enhancer-binding protein-beta during adipogenesis. Proc Natl Acad Sci USA 97(23):12446-12450.
107. Tiedje C, Ronkina N, Tehrani M, Dhamija S, Laass K, Holtmann H, Kotlyarov A, Gaestel M. 2012. The p38/MK2-driven exchange between tristetraprolin and HuR regulates AU-rich element-dependent translation. PLoS Genet 8(9): e1002977.
108. Tnani M, Aliau S, Bayard B. 1998. Localization of a molecular form of interferon-regulated RNase L in the cytoskeleton. J Interferon Cytokine Res 18(6):361-368.
109. Tomecki R, Dziembowski A. 2010. Novel endoribonucleases as central players in various pathways of eukaryotic RNA metabolism. Rna-a Publication of the Rna Society 16(9): 1692-1724.
110. Trojanowicz B, Dralle H, Hoang-Vu C. 2011. AUF1 and HuR: possible implications of mRNA stability in thyroid function and disorders. Thyroid Res 4 Suppl 1:S5.
111. Ubeda M, Schmitt-Ney M, Ferrer J, Habener JF. 1999. CHOP/GADD153 and methionyl-tRNA synthetase (MetRS) genes overlap in a conserved region that controls mRNA stability. Biochem Biophys Res Commun 262(1):31-38.
112. Uchida N, Hoshino S, Imataka H, Sonenberg N, Katada T. 2002. A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap/Poly(A)-dependent translation. J Biol Chem 277(52):50286-50292.
113. Uehata T, Akira S. 2013. mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1. Biochim Biophys Acta 1829(6-7):708-713.
114. Varnum BC, Lim RW, Sukhatme VP, Herschman HR. 1989. Nucleotide sequence of a cDNA encoding TIS11, a message induced in Swiss 3T3 cells by the tumor promoter tetradecanoyl phorbol acetate. Oncogene 4(1):119-120.
115. Wang WG, Furneaux H, Cheng HM, Caldwell MC, Hutter D, Liu YS, Holbrook N, Gorospe M. 2000. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 20(3):760-769.
116. Williams BR. 2001. Signal integration via PKR. Sci STKE 2001(89):re2.
117. Worthington M, Rowlett R, Pelo J, Harp M, Chrestensen C, Schroeder M, Sturgill TW. 2005. Regulation of TNF expression at the post-transcriptional level: Polya binding protein inhibits tristetraprolin-mediated degradation of TNF Rna via a PABP-TTP complex. Gastroenterology 128(4):A218.
118. Wreschner DH, James TC, Silverman RH, Kerr IM. 1981a. Ribosomal RNA cleavage, nuclease activation and 2-5A(ppp(A2¢p)nA) in interferon-treated cells. Nucleic Acids Res 9(7):1571-1581.
119. Wreschner DH, McCauley JW, Skehel JJ, Kerr IM. 1981b. Interferon action-sequence specificity of the ppp(A2¢p)nAdependent ribonuclease. Nature 289(5796):414-417.
120. Xiang Y, Wang ZF, Murakami J, Plummer S, Klein EA, Carpten JD, Trent JM, Isaacs WB, Casey G, Silverman RH. 2003. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2¢,5¢-oligoadenylates. Cancer Res 63(20):6795-6801.
121. Yang F, Schoenberg DR. 2004. Endonuclease-mediated mRNA decay involves the selective targeting of PMR1 to polyribosomebound substrate mRNA. Mol Cell 14(4):435-45.
122. Ye S, Guo Q, Tang JP, Yang CD, Shen N, Chen SL. 2007. Could 2¢ 5¢-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study. Clinical Rheumatology 26(2): 186-190.
123. Yin T, Yang YC. 1993. Protein tyrosine phosphorylation and activation of primary response genes by interleukin 11 in B9-TY1 cells. Cell Growth Differ 4(7):603-609.
124. Zhou A, Hassel BA, Silverman RH. 1993. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72(5):753-765.
125. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. 1997. Interferon action and apoptosis are defective in mice devoid of 2¢,5¢-oligoadenylate-dependent RNase L. EMBO J 16(21): 6355-6363.
126. Zhou AM, Molinaro RJ, Malathi K, Stlverman RH. 2005. Mapping of the human RNASEL promoter and expression in cancer and normal cells. J Interferon Cytokine Res 25(10): 595-603.
127. Zhou JH, Liu CY, Back SH, Clark RL, Peisach D, Xu ZH, Kaufman RJ. 2006. The crystal structure of human IRE1 luminal domain reveals a conserved dimerization interface required for activation of the unfolded protein response. Proc Natl Acad Sci USA 103(39):14343-14348.